Sign in
Enrolling by invitationPhase 3

NPNP-001 for pain in people with knee osteoarthritis, compared with Conjuran

Tests NPNP-001 against Conjuran for easing pain in people with knee osteoarthritis.

Key facts

Who runs it
PharmaResearch Co.,Ltd
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Pivotal Clinical Trial to Evaluate the Efficacy and Safety After NPNP-001 Application in Patients with Knee Osteoarthritis.
Status
Enrolling by invitation
Phase
Phase 3
People taking part
260 people, planned
Started
8 Jan 2025
Planned end
Jun 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • NPNP-001
  • Conjuran
Record updated
20 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 or older with painful knee osteoarthritis that did not improve with usual non-surgical care. It compares two knee injection devices, NPNP-001 and Conjuran.

Age
40 years or older
Sex
Men and women
Disease stage
Knee osteoarthritis in one or both knees, by ACR criteria. Kellgren Lawrence Grade 1 to 3 on X-ray. Pain on standing or walking of at least 40 mm on a 100 mm scale in at least one knee.
Earlier treatment
Medicines or physical therapy for at least 3 months did not help. No sodium polynucleotide or hyaluronic acid (HA) knee injections in the last 6 months. No steroid knee injections in the last 3 months. No steroid pills or shots in the last 1 month. No cell or gene therapy in the knee ever. No knee surgery in the last 6 months, and no knee replacement in the treated knee.

Main reasons for not taking part

  • BMI of 35 kg/m² or more
  • Rheumatoid arthritis or other types of arthritis
  • Allergy to the device, a positive skin prick test, or allergy to salmon, shrimp or crab
  • Use of blood thinners within 2 weeks before treatment, except low-dose aspirin
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Adult males and females aged 40 years or older as of the date of written consent
  • Patients diagnosed with unilateral or bilateral knee osteoarthritis according to the American College of Rheumatology (ACR) clinical diagnostic criteria, experiencing knee joint pain, and meeting at least three of the following conditions:; Age > 50 years; Morning stiffness < 30 minutes; Crepitus; Bony tenderness; Bony enlargement; No palpable warmth of the synovium
  • At least one knee joint with a Weight-Bearing Pain (100 mm-VAS) score ≥ 40 mm, measured at the screening visit
  • X-ray results from within 6 months prior to screening or at the screening visit indicating that the target lesion of knee osteoarthritis corresponds to Kellgren Lawrence Grade 1 to 3
  • Patients with knee osteoarthritis who have not responded to conservative treatments such as pharmacotherapy or physical therapy for at least 3 months prior to screening
  • Patients who can adequately understand and complete the efficacy assessment questionnaires
  • Patients who voluntarily agree to the informed consent form after receiving an explanation of the purpose, methods, and effects of the clinical trial
  • Patients who agree to refrain from using any pharmacotherapy for knee osteoarthritis other than the rescue medication during the clinical trial period
  • Patients who are able to undergo allergy testing (skin prick test)

Who cannot take part

  • Patients who have undergone surgical procedures on the target knee joint or cartilage regeneration surgeries (such as microfracture, autologous chondrocyte implantation, etc.) within 6 months prior to screening (however, patients with surgical history on the opposite knee or hip joints will only be excluded if it is likely to impact the clinical evaluation of the target knee joint)
  • Patients who have taken anticoagulants (including warfarin, NOACs [Non-vitamin K Oral Anti-Coagulants], antiplatelet agents [aspirin, clopidogrel; however, low-dose aspirin [100 mg, maximum 300 mg/day] is excluded], thrombolytics [urokinase, alteplase, etc.]) within 2 weeks prior to the application of the investigational device
  • Patients with a positive allergy test (skin prick test) result for the investigational device conducted at screening or those with hypersensitivity to components of the investigational device used in this clinical trial (including allergies to salmon, shrimp, and crab)
  • Patients who have participated in another clinical trial and received investigational products or medical devices within 6 months prior to screening
  • Patients with conditions that are deemed likely to affect the efficacy and safety assessment of this clinical trial (however, those who are considered eligible by the investigator may be enrolled):; Patients with severe painful conditions such as septic arthritis, autoimmune diseases, gout, recurrent pseudogout, Paget's disease, etc.(e.g. Sudeck's atrophy, herniated discs, etc.), as well as those with joint fractures, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary osteochondrosis, genetic diseases (hyperkinesis, etc.), collagen gene abnormalities; Patients with hemorrhagic disorders, hemostatic disorders, CNS diseases, cancer, AIDS, heart disease, kidney disease, uncontrolled diabetes and hypertension, severe medical or psychiatric conditions, and patients with hypersensitivity to local anesthetics
  • Patients with skin abnormalities at the injection site that may affect invasive procedures, such as infections or skin diseases
  • Patients with a history of knee joint replacement surgery in the target joint
  • Patients who are expected to start medication for depression or anxiety disorders during the clinical trial period
  • Patients who have received the following medications prior to screening:; Patients who have received sodium polynucleotide and/or hyaluronic acid(HA) injections into the target knee joint within 6 months prior to screening; Patients who have received steroid injections into the target knee joint within 3 months prior to screening; Patients who have used systemic steroids within 1 month prior to screening (topical and inhaled steroids are excluded); Patients who have received cell therapy or gene therapy into the target knee joint prior to screening
  • Patients with a Body Mass Index (BMI) ≥ 35 kg/m² at screening
  • Patients with rheumatoid arthritis or other types of arthritis such as traumatic, metabolic, etc
  • Patients with severe osteoarthritis symptoms in other joints (e.g., hip joint) that may affect pain assessment in the knee joint (polyarticular joint pain)
  • Patients with severe joint effusion confirmed through tests such as the patellar tap test
  • Pregnant or breastfeeding women, women of childbearing potential who plan to become pregnant during the clinical trial period and for 3 months after, or men who do not intend to use appropriate contraceptive methods*; Hormonal contraceptives, intrauterine devices (such as Implanon), dual barrier methods (using both male condoms and cervical caps), and sterilization procedures (vasectomy, bilateral tubal ligation, etc.)
  • Patients with knee joint instability

Where in South Korea

  • Seoul St. Mary's HospitalSeoul, South KoreaEnrolling by invitation

About the trial

What the trial wants to find out

This study was designed to demonstrate non-inferiority and safety in pain reduction after NPNP-001 application in patients with knee osteoarthritis.

The 2 groups in the trial

  • NPNP-001Treatment being tested
  • ConjuranExisting treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-blinded, Active-controlled, Non-inferiority, Pivotal Clinical Trial to Evaluate the Efficacy and Safety in Pain Reduction After NPNP-001 Application in the Knee Joint of Patients with Knee Osteoarthritis
Plain-language title
NPNP-001 for pain in people with knee osteoarthritis, compared with ConjuranGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
20 January 2025